Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2006-10-10
2006-10-10
Romeo, David (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S085100, C930S144000
Reexamination Certificate
active
07118750
ABSTRACT:
A modified human TNFα molecule is capable of raising neutralizing antibodies towards unmodified human TNFα following administration of the modified TNFα to a human host, wherein one or more peptide fragments of the human TNFα molecule has been substituted by one or more peptides containing immunodominant T cell epitopes or a truncated form of the molecule containing the immunodominant epitope and one or both flanking regions of the human TNFα-molecule containing at least one TNFα B cell epitope, wherein the substitution introduces a substantial change in the amino acid sequence of any one of the strands of the front β-sheet, in any one of the connecting loops, or in any one of the B′, I, or D strands of the back β-sheet.
REFERENCES:
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 0 251 037 (1988-01-01), None
patent: 0 619 372 (1994-10-01), None
patent: WO90/07579 (1990-07-01), None
patent: WO92/19746 (1992-11-01), None
patent: WO 93/05810 (1993-04-01), None
patent: WO95/05849 (1995-03-01), None
Cooke et al. Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med. Feb. 1, 1994;179(2).
Werdelin, O, et al, Immunological Reviews, 1988, No. 106, pp. 181-193.
Langstein, H. et al, Cancer Research. vol. 51, 1991, pp. 2302-2306.
Arend, W. et al, Arthritis and Rheumatism, vol. 33, No. 3, Mar. 1990, pp. 305-315.
Elliott, M. et al, LANCET, vol. 344, Oct. 22, 1994, pp. 1105-1110.
van Dullemen, H. et al, GASTROENTEROLOGY, vol. 109, No. 1 (1995), pp. 129-135.
Jones, E. et al, “Crystal Structure of TNF”, Tumor Necrosis Factors, Structure, Function and Mechanism of Action, edited by Bharat B. Aggarwal and Jan Vilcek, 1992, Marcel Dekker, Inc, New York, Chapter 5, pp. 92-127.
Smith, R. et al, J. Biol. Chemistry, vol. 252, May 1987, pp. 6951-6954.
Davis, J. et al, BIOCHEMISTRY, vol. 26, No. 5, 1987, pp. 1322-1326.
Yamagishi et al, Protein Engineering, vol. 3, No. 8, 1990 pp. 713-719.
Goh, C. et al, Protecin Engineering, vol. 4, No. 4, 1991, pp. 385-389.
Tsujimoto, M. et al, J. Biochem, vol. 101, No. 4, 1987, pp. 919-925.
Wang, A. et al, SCIENCE, vol. 228, 1985, pp. 149-154.
Nedwin, G. et al, Nucleic Acids Research, vol. 13, No. 17, 1985, pp. 6361-6373.
Shirai, T. et al, NATURE, vol. 313, Feb. 28, 1985, pp. 803-806.
Panina-Bordignon, P. et al, Eur. J. Immunol, vol. 19, 1989, pp. 2237-2242.
Pennica, D. et al, NATURE, vol. 312, Dec. 1984, pp. 724-729.
Jensen, M. et al, 6th International TNF Congress 1996 Abstract.
Dalum Iben
Elsner Henrik
Jensen Martin Roland
Mouritsen Søren
Jacobson & Holman PLLC
Pharmexa A/S
Romeo David
LandOfFree
Modified TNF-alpha molecules, DNA encoding such and vaccines... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified TNF-alpha molecules, DNA encoding such and vaccines..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified TNF-alpha molecules, DNA encoding such and vaccines... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3691247